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Table. XIENCE V Planned Overlap for Very Long Coronary Lesions (Pooled SII,
SIII, SIV, SV, Small Vessel, XV USA)
















28.07  2.44 (500) 47.06  13.69 (328) <0.0001
Mean Total Stent
Length (mm)





TLF 10.1% (47/466) 9.0% (28/311) 0.7102
MACE 10.1% (47/466) 9.3% (29/311) 0.8056
Non-Hierarchical
Subject Counts
All Death 2.8% (13/466) 4.2% (13/311) 0.3132
Cardiac Death 2.1% (10/466) 2.3% (7/311) 1.0000
All MI 3.9% (18/466) 4.8% (15/311) 0.5869
Target Vessel MI 3.6% (17/466) 4.5% (14/311) 0.5780
ID/CI-TLR 5.6% (26/466) 5.1% (16/311) 0.8721
ARC Stent Thrombosis
Deﬁnite 0.7% (3/454) 1.0% (3/307) 0.6898
Deﬁnite/Probable 1.5% (7/454) 1.6% (5/307) 1.0000
TLF ¼ cardiac death, target vessel MI, ID/CI-TLR; MACE ¼ cardiac death, all MI, ID/CI-TLR
P-values for per lesion analyses are from t-test; P-values for per subject analyses are from
Fisher's exact test; All p-values displayed are two-tailed and not from pre-speciﬁed hypothesis
testing and are displayed for information only
Denominators for per subject analyses (except for Arc Stent Thrombosis) exclude subjects
who are truly lost-to-follow-up, deﬁned as subjects who are lost to follow-up through given
timepoint without any DMR event (all death, all MI, all revascularization).
ARC stent thrombosis denominators exclude subjects who were early terminated and did not
have deﬁnite or probable ARC stent thrombosis
WHO-based per protocol deﬁnitions were used for MI except for SPIRIT V, where ARC MI
deﬁnitions were used
For per lesion analysis, only lesions with planned overlapping stents were included.
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Background: The current study compared the novel Biotronik Osiro stent, eluting
sirolimus from a biodegradable polymer PLLA, applied on a thin-strut (60 mm)
Silicon-Carbide coated Cobalt-Chromium stent with the Abbott Xience PrimeTM
stent. The primary endpoint was non-inferiority for in-stent Late Lumen Loss (LLL) at
9 months in de novo coronary artery lesions.
Methods: We performed a prospective, multicenter, randomized controlled study
(RCT) in 452 subjects (63.410.0 yrs) with symptomatic coronary artery disease due
to de novo stenotic lesions in native coronary arteries with a RVD  2.25 mm, Ø 4.0
mm and a lesion length  26 mm. Subjects were randomly assigned 2:1 to receive the
Osiro SES or the Xience Prime EES. The primary endpoint of the study is in-stent
LLL assessed at 9 months and analyzed according to the intention-to-treat principle.
All subjects were enrolled between July 5, 2011- March 23, 2012 and were invited to
undergo repeat angiography at 9 months. Clinical follow up visits are performed at 1,
6, 12 months and annually for up to 5 years after the procedure. All angiographic
images were analyzed by (R. Waksman, Medstar, Washington DC, USA). All clinical
events were adjudicated by 3 independent cardiologists (MD:s). Clinicaltrials.gov no.
NCT01356888
Results: Both study groups showed comparable populations in terms of demo-
graphics, current risk factors, clinical history and lesion/vessel characteristics. The in-
stent late lumen loss at 9-months was 0.10  0.32 mm for the Osiro compared to 0.11
 0.29 mm for the Xience with a p-value of 0.9849. The non-inferiority hypothesis
was thereby conﬁrmed with p-value<0.0001. The clinical endpoint of Target Lesion
Failure (TLF) at 9 month was 4.8% for the Osiro compared to 5.3% for the Xience
with a p-value of 0.9849.
Conclusions: In this RCT the Osiro SES with a biodegradable polymer was non-
inferior to the Xience Prime EES with a durable polymer for the primary angio-
graphic endpoint of in-stent late loss at 9 months. Clinical event rates were low and
comparable with both Osiro and Xience Prime through 9 months. Results of the
clinical event rates at 12 month are now being analyzed and will be presented at the
meeting for the ﬁrst time.
TCT-174
Clinical Outcomes after PCI Treatment of Very Long Coronary Lesions with the
XIENCE V Everolimus Eluting Stent (EES): Pooled Analysis from the SPIRIT
and XIENCE V USA Prospective Multi-Center Trials
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Background: Very long ( 35 mm) coronary lesions are more complex than shorter
lesions. Single-stent treatment of very long coronary lesions is limited by maximum
stent length, and since stents in the everolimus-eluting cobalt-chromium XIENCE
family of coronary stents with lengths > 28 mm have only recently become available,
a predetermined planned overlap strategy is most often used for treatment of lesions 
35 mm in length. There is a substantive body of clinical data for XIENCE V (Abbott
Vascular, Santa Clara), but outcomes for very long coronary lesions using Xience V
have not previously been reported.
Methods: The pooled "XIENCE V Planned Overlap" dataset combines patients
treated using XIENCE V with a predetermined planned overlap strategy from six
prospective multi-center trials: SPIRIT II, SPIRIT III, SPIRIT IV, SPIRIT V, SPIRIT
Small Vessel, and XIENCE V USA. Analyses were performed on subjects with
lesions > 24 to < 35 mm in length and  35 mm in length. Clinical outcomes
evaluated at 1 year included TLF and MACE, all death, cardiac death, all MI, target
vessel MI, ID/CI-TLR, and deﬁnite and deﬁnite/probable stent thrombosis. All
endpoint events were adjudicated by independent clinical evaluation committees.
Results: There were 482 patients with 500 lesions > 24 to < 35 mm in length, and
323 patients with 328 lesions  35 mm in length. The Table shows that 1-yearB56 JACC Vol 62/18/Suppl B j October 27–November 1, 2013outcomes were not signiﬁcantly different in very long lesions compared to those > 24
to < 35 mm.
Conclusions: Despite inherent increased complexity of very long coronary lesions,
XIENCE V PCI treatment resulted in similar clinical outcomes at 1 year for very long
( 35 mm) coronary lesions as for shorter (> 24 to < 35 mm) lesions. Based on these
clinical data, XIENCE V PCI treatment of lesions  35 mm appears as effective and
safe as PCI for shorter lesions.TCT-175
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Background: Patients with diabetes mellitus were shown to have less favorable
outcomes after saphenous vein graft (SVG) intervention with bare metal stents while
its impact with drug-eluting stents (DES) is not clearly deﬁned. We aimed to compare
clinical outcomes in diabetic patients who underwent SVG percutaneous coronary
interventions (PCI) with the use of DES.
Methods: From our PCI registry we retrospectively analyzed 477 consecutive patients
with prior CABG who underwent SVG PCI with the implantation of DES stratiﬁed by
presence or absence of diabetes. The primary end point was 1-year major cardiac eventj TCT Abstracts/POSTER/Bare Metal and Drug-Eluting Stent Studies











(95% CI) p Value
Composite
end point*
38(10.0%) 27(6.4%) 1.712(1.043-2.809) 0.033
All-cause death 25(6.6%) 12(2.8%) 2.425(1.218-4.829) 0.012
Cardiac death 15(3.9%) 6(1.4%) 2.837(1.101-7.313) 0.031
www.jacctctabstracts2013.com TUESDAY, OCTOBER 29, 2013, 3:30 PM–5:30 PM(MACE) rate, deﬁned as death, Q-wave myocardial infarction, and target lesion
revascularization.
Results: Baseline clinical characteristics, including mean graft age (12077 vs.
13186 months, p¼0.14), were similar between groups, except for higher prevalence
of hypertension, chronic renal insufﬁciency and higher body mass index in the dia-
betic group. Among the 604 SVG lesions treated with DES, the angiographic and
procedural characteristics were well matched, except for the higher rate of distal
protection device use (32% vs. 29%, p¼0.007) in the diabetic group. The 1-year
MACE rate (21% vs. 15%, p¼0.12) and all-cause mortality rate (7.6% vs. 6.7%,
p¼0.86) were similar between the two groups. After adjustment for the relevant
clinical co-variables, diabetes was not associated with the composite end point.Nonfatal MI 6(1.6%) 11(2.6%) 0.664(0.242-1.822) 0.426
All-cause
death or MI
30(7.9%) 22(5.2%) 1.623(0.934-2.821) 0.086
Stroke 9(2.4%) 5(1.2%) 2.355(0.788-7.042) 0.125
TVR 14(3.7%) 7(1.7%) 2.476(0.998-6.144) 0.051
TLR 37(9.7%) 50(11.8%) 0.945(0.615-1.452) 0.796Conclusions: Unlike the results seen in de novo lesions, when DES are utilized in PCI
of SVG lesions, the presence of diabetes is no loner a discriminator of the short- and
long-term outcomes.
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Background: A few data were available regarding the association between percuta-
neous coronary intervention (PCI) with drug-eluting stent (DES) and blood pressure
(BP) variability for long-term clinical outcomes.
Methods: Total 994 consecutive patients undergoing PCI with DES from March 2003
to August 2007 were enrolled. We measured patients' BP in a routine ward envi-
ronment just before transferring to the cath lab and in the cath lab before arterial
puncture (ward-to-cath lab BP) and assessed the differences of systolic and diastolic
BP, and heart rate. The subjects were divided into 2 groups according to the differ-
ences of ward-to-cath lab systolic BP: high variability group (n¼383) as the absolute
difference > 20mmHg and low variability group (n¼424) as the absolute difference
 20mmHg. The primary outcome of interest was the composite of death, myocardial
infarction (MI), or stroke.
Results: In 807 patients (522 males, 6010 years), the mean differences of systolic
and diastolic BP, and heart rate were 26.518.9 and 11.810.2 mmHg and 10.18.9
beats/min, respectively. During follow-up of 1878864 days, composite rate of death,
MI, or stroke was higher in the high variability group than the low variability group
(10.2% vs. 6.4%; adjusted hazard ratio, 1.96; 95% conﬁdence interval, 1.14-3.38; Cox
p¼0.016). The rates of death or MI (7.8% vs. 5.2%, p¼0.09) and stroke (2.3% vs.
1.2%, p¼0.17) were also numerically higher in the high variability group, which did
not reach statistical signiﬁcance. However, there were no signiﬁcant differences in
clinical outcomes for the ward-to-cath lab variability of diastolic BP and heart rate.JACC Vol 62/18/Suppl B j October 27–November 1, 2013 j TCT AbstrConclusions: This result suggests the variability of ward-to-cath lab systolic BP may
contribute to the elevated adverse cardiovascular risk in patients undergoing PCI with
DES.
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Background: The thin-strut, everolimus-eluting, platinum chromium PROMUS
Element stent (Boston Scientiﬁc, Natick MA) has shown favorable outcomes at 1 and
2 years post-implantation in the treatment of de novo lesions in small vessels
(2.25mm to <2.5mm in baseline diameter) and long lesions (>24 to 34mm in
length), but longer-term follow-up has not been previously reported.
Methods: PLATINUM SV and LL are prospective, single-arm, multinational studies
that enrolled patients with angina pectoris or documented silent ischemia and one de
novo native coronary artery target lesion. PLATINUM SV enrolled 94 subjects with
baseline vessel diameter 2.25mm to <2.50mm and lesion length 28 mm, and
PLATINUM LL enrolled 102 patients with a target lesion >24 to 34mm long with
reference diameter 2.50 to 4.25mm.
Results: Patients were predominantly male (SV: 72.3%, LL: 62.7%) and approxi-
mately one third had diabetes (SV: 42.6%, LL: 30.0%). The mean baseline vessel
diameter in SV was 2.040.26 mm, and mean lesion length in LL was 24.388.21
mm. The primary endpoint, 1-year target lesion failure (deﬁned as cardiac death,
myocardial infarction related to the target vessel, or ischemia-driven target lesion
revascularization), was 2.4% for SV and 3.2% for LL, signiﬁcantly less than the
prespeciﬁed performance goals of 21.1% for SV and 19.4% for LL (P<0.001 for
each). At 3 years, outcomes for 84 evaluable patients in the SV trial were 4 (4.6%)
TLFs, 2 (2.4%) TLRs, 2 (2.3%) cardiac deaths, 1 (1.1%) non-cardiac deaths, and 1
(1.2%) MI, with no ARC deﬁnite/probable ST events. Through 2-year follow-up in
95/100 patients in LL, there were 8 (8.8%) TLFs, 5 (5.2%) TLRs, 3 (3.6%) cardiac
deaths, 1 (1.0%) non-cardiac death, and no MIs or ARC deﬁnite/probable ST. Three-
year results for LL will be available at the time of the meeting.
Conclusions: The PROMUS Element stent has demonstrated low target lesion failure
and revascularization rates, and acceptable safety outcomes with longer-term follow-
up in patients with small vessels and long lesions. The three-year results from these
studies will be available for presentation for the ﬁrst time at TCT 2013.acts/POSTER/Bare Metal and Drug-Eluting Stent Studies B57
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